Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.

Clinical and translational science - 1 Apr 2025

Lubomirov Rubin, Pérez-Ramos Laura, Fudio Salvador, Asín-Prieto Eduardo, Ibarra-Gómez Laura, Zubiaur Pablo

Abstract excerpt

Lurbinectedin is an oncogenic transcription inhibitor indicated for the treatment of small cell lung cancer (SCLC), which has also shown activity against other malignancies. In this work, two independent cohorts of 180 (discovery cohort) and 719 (validation cohort) cancer patients receiving lurbinectedin in Phases I, II, or III clinical trials were enrolled. Using a population pharmacokinetic (popPK) model of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 4 or More Rings

Share to Lung Neoplasms

Share to Metabolic Clearance Rate

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Small Cell Lung Carcinoma

Source

Open in PubMed Open full text

Identifiers

PMID: 40146606
DOI: 10.1111/cts.70173
PMCID: PMC11949125

Genes

CYP3A4
CYP3A5
ABCB1
ARNT
FOXA3
NR1H4
NR5A2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin.PMID 40146606Read ↗

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?Semantic proximity Read ↗

Extensive prediction of drug response in mutation-subtype-specific LUAD with machine learning approach.Semantic proximity Read ↗

Unveiling the Mechanism of Lurbinectedin’s Action and Its Potential in Combination Therapies in Small Cell Lung CancerSemantic proximity Read ↗

Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung CancerSemantic proximity Read ↗

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related PharmacogenomicsSemantic proximity Read ↗

Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients.Semantic proximity Read ↗

An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers.Semantic proximity Read ↗

Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis.Semantic proximity Read ↗

Pharmacokinetics and Pharmacogenomics of Ribociclib in Black Patients with Metastatic Breast Cancer: The LEANORA studySemantic proximity Read ↗

CLM296: a highly selective inhibitor targeting ALDH1A3-driven tumor growth and metastasis in breast cancerSemantic proximity Read ↗

Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.